A 36-month study using data from the American Academy of Ophthalmology IRIS® Registry demonstrated that Sight Sciences’ OMNI® Surgical System significantly reduced intraocular pressure (IOP) and medication dependence in patients with primary open-angle glaucoma (POAG). This research is notable because it analyzes standalone OMNI use, independent of cataract surgery, providing crucial real-world data on its long-term effectiveness. The study, published in the •American Journal of Ophthalmology•, involved 230 eyes of 196 POAG patients and was led by Dr. Nathan M. Radcliffe of Mount Sinai School of Medicine.
This study’s findings are vital for ophthalmologists and POAG patients as they offer evidence of a minimally invasive glaucoma surgery (MIGS) option effective over three years. Specifically, the demonstrated sustained IOP reduction and decreased medication needs suggest a potential shift in treatment paradigms. This offers a valuable alternative to traditional glaucoma surgeries and long-term reliance on medication, especially for patients who are not candidates for or prefer to avoid cataract surgery. The ability to achieve significant IOP reduction without implants further enhances the appeal of OMNI as a MIGS procedure.
The study showed mean IOP reductions ranging from 5.6 to 7.1 mmHg over 36 months, with even greater reductions observed in patients with higher baseline IOPs (up to 8.9 mmHg). Medication usage also decreased significantly through 18 months post-operatively, and those with lower baseline IOP saw this reduction sustained through 36 months. The utilization of the IRIS Registry, a comprehensive database capturing millions of patient encounters, underscores the robust nature of these findings and their applicability to real-world clinical practice.
This positive long-term data strengthens OMNI’s position as a viable treatment option for POAG, potentially increasing its adoption among ophthalmologists. It also reinforces the trend toward minimally invasive procedures in glaucoma management, offering patients a less burdensome approach with sustained benefits. The study’s focus on standalone use broadens the potential patient population for OMNI and could lead to earlier intervention for glaucoma, potentially slowing disease progression and preserving vision.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.